Suppliers / Celltrion Pharm

Celltrion Pharm

South Korea 108 employees 4 duplicate records merged Updated 9 July 2026

Celltrion Pharm is a finished-dose manufacturer based in South Korea. It appears in 17 regulatory filings across 3 regulators, without an active US DMF or CEP on file. Its filings concentrate with DAV (Vietnam), ARCSA (EC) and MINSA (CR). Its GMP standing is certified by US FDA, EMA and ANVISA (Brazil). Its most recent recorded inspection, by US FDA, closed on 23 July 2024 as VAI.

0
active US DMFs
0
valid CEPs
3
registered plants 1 with an FDA FEI number
17
filings across 3 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
1 of 1 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 23 July 2024 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
South, South Korea 3012279978
CHUNGCHEONGBUK-DO, South Korea Not on file
Cheongju, South Korea Not on file

Filings and GMP by regulator

Regulator Filings GMP certificates
DAV (Vietnam) 10 None
ARCSA (EC) 5 None
MINSA (CR) 2 None
US FDA None 1
EMA None 1
ANVISA (Brazil) None 1

Comparing suppliers?

Choose your molecules and target markets. Celltrion Pharm comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 23 July 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates